Cipher Pharmaceuticals, Inc. (CPH.TO)
14.10
0.00 (0.00%)
CAD |
TSX |
Aug 24, 16:00
Cipher Pharmaceuticals Enterprise Value : 345.95M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 345.95M |
| August 21, 2026 | 345.95M |
| August 20, 2026 | 351.54M |
| August 19, 2026 | 352.55M |
| August 18, 2026 | 351.28M |
| August 17, 2026 | 351.28M |
| August 14, 2026 | 346.96M |
| August 13, 2026 | 343.15M |
| August 12, 2026 | 346.20M |
| August 11, 2026 | 443.79M |
| August 10, 2026 | 434.14M |
| August 07, 2026 | 433.63M |
| August 06, 2026 | 438.71M |
| August 05, 2026 | 417.62M |
| August 04, 2026 | 421.43M |
| July 31, 2026 | 415.33M |
| July 30, 2026 | 405.93M |
| July 29, 2026 | 403.38M |
| July 28, 2026 | 402.11M |
| July 27, 2026 | 405.16M |
| July 24, 2026 | 400.59M |
| July 23, 2026 | 405.42M |
| July 21, 2026 | 408.72M |
| July 20, 2026 | 404.91M |
| July 17, 2026 | 404.40M |
| Date | Value |
|---|---|
| July 16, 2026 | 404.15M |
| July 15, 2026 | 410.50M |
| July 14, 2026 | 413.55M |
| July 13, 2026 | 417.11M |
| July 10, 2026 | 422.95M |
| July 09, 2026 | 417.87M |
| July 08, 2026 | 419.90M |
| July 07, 2026 | 428.04M |
| July 06, 2026 | 425.75M |
| July 03, 2026 | 423.97M |
| July 02, 2026 | 416.35M |
| June 30, 2026 | 411.26M |
| June 29, 2026 | 402.48M |
| June 26, 2026 | 408.32M |
| June 25, 2026 | 416.19M |
| June 24, 2026 | 409.84M |
| June 23, 2026 | 406.54M |
| June 22, 2026 | 406.29M |
| June 19, 2026 | 406.29M |
| June 18, 2026 | 402.48M |
| June 17, 2026 | 396.38M |
| June 16, 2026 | 403.24M |
| June 15, 2026 | 402.99M |
| June 12, 2026 | 405.78M |
| June 11, 2026 | 397.91M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| HLS Therapeutics, Inc. | 155.36M |
| Bausch Health Cos., Inc. | 31.70B |
| BioSyent, Inc. | 169.97M |
| Revive Therapeutics Ltd. | 10.94M |
| Knight Therapeutics, Inc. | 873.52M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 5.556M |
| Revenue (Quarterly) | 16.71M |
| Total Expenses (Quarterly) | 11.15M |
| EPS Diluted (Quarterly) | 0.2138 |
| Gross Profit Margin (Quarterly) | 65.58% |
| Profit Margin (Quarterly) | 33.26% |
| Earnings Yield | 11.00% |
| Operating Earnings Yield | 7.30% |
| Normalized Earnings Yield | 11.00 |